Condition
Neuromyelitis Optica Spectrum Disorder Attack
Total Trials
6
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 4 (1)
Trial Status
Active Not Recruiting1
Not Yet Recruiting1
Recruiting1
Terminated1
Unknown1
Withdrawn1
Clinical Trials (6)
Showing 6 of 6 trials
NCT07738952Phase 1Not Yet RecruitingPrimary
Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder
NCT07184840Phase 2Active Not RecruitingPrimary
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
NCT07410039Phase 4RecruitingPrimary
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
NCT06673394Phase 2WithdrawnPrimary
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
NCT04131764Terminated
Diagnosis of ON With or Without MS or NMOSD
NCT05605951Unknown
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
Showing all 6 trials